Predictive methylation signature for gemcitabine sensitivity in pancreatic ductal adenocarcinoma: A pathway to personalized treatment.

被引：0
作者：
Sherpally, Deepak
Jeepalyam, Sravan
Puram, Harshitha
Manne, Ashish
机构：
[1] Metropolitan Hosp Ctr, New York, NY USA
[2] Stormont Vail Hlth, Topeka, KS USA
[3] Univ Cincinnati, Cincinnati, OH USA
[4] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.768
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：768 / 768
页数：1
相关论文
共 50 条
  • [21] Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine
    Lee Cheng Phua
    Shixu Goh
    David Wai Meng Tai
    Wei Qiang Leow
    Syed Muhammad Fahmy Alkaff
    Chung Yip Chan
    Juinn Huar Kam
    Tony Kiat Hon Lim
    Eric Chun Yong Chan
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 277 - 289
  • [22] Thermosensitive Liposomes for Gemcitabine Delivery to Pancreatic Ductal Adenocarcinoma
    Aparicio-Lopez, Cesar B.
    Timmerman, Sarah
    Lorino, Gabriella
    Rogers, Tatiana
    Pyle, Marla
    Shrestha, Tej B.
    Basel, Matthew T.
    CANCERS, 2024, 16 (17)
  • [23] THE HENT1 IMMUNOHISTOCHEMISTRY DIAGNOSTIC TEST IS PREDICTIVE OF GEMCITABINE OUTCOME IN PANCREATIC DUCTAL ADENOCARCINOMA
    Raponi, M.
    Isaacson, J.
    Hahn, H.
    Bartosiewicz, M.
    Magnusson, A.
    Lin, K.
    Rolfe, L.
    Allen, A.
    Picozzi, V.
    ANNALS OF ONCOLOGY, 2012, 23 : 236 - 236
  • [24] The hENT1 Immunohistochemistry Diagnostic Test is Predictive of Gemcitabine Outcome in Pancreatic Ductal Adenocarcinoma
    Raponi, Mitch
    Isaacson, Jeff
    Hahn, Hejin
    Bartosiewicz, Mike
    Magnusson, Andrea
    Lin, Kevin
    Rolfe, Lindsey
    Allen, Andrew
    Picozzi, Vincent
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S84 - S85
  • [25] dCK expression and gene polymorphism with gemcitabine chemo-sensitivity in patients with pancreatic ductal adenocarcinoma
    Altaf, K.
    Xiong, J.
    Ke, N.
    Wang, Y.
    Liu, X.
    BRITISH JOURNAL OF SURGERY, 2016, 103 : 36 - 37
  • [26] Treatment of pancreatic ductal adenocarcinoma (PDAC) by argyrin F (AF) plus gemcitabine (G)
    Plentz, Ruben R.
    Chen, Xi
    Barat, Samarpita
    Bozko, Przemyslaw
    Bui, Cuong
    Sipos, Bence
    Kalesse, Markus
    Malek, Nisar P.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [27] Development and Validation of the Predictive and Prognostic ChemoResist Signature in Resected Pancreatic Ductal Adenocarcinoma: Multicohort Study
    Huang, Lei
    Han, Quanli
    Zhao, Liangchao
    Wang, Zhikuan
    Dai, Guanghai
    Shi, Yan
    ANNALS OF SURGERY, 2025, 281 (04) : 632 - 644
  • [28] Extracellular Vesicles Inhibit the Response of Pancreatic Ductal Adenocarcinoma Cells to Gemcitabine and TRAIL Treatment
    Rimmer, Ella
    Rashid, Sadaf
    Kraev, Igor
    Miralles, Francesc
    Elia, Androulla
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (14)
  • [29] A microRNA meta-signature for pancreatic ductal adenocarcinoma
    Frampton, Adam E.
    Giovannetti, Elisa
    Jamieson, Nigel B.
    Krell, Jonathan
    Gall, Tamara M. H.
    Stebbing, Justin
    Jiao, Long R.
    Castellano, Leandro
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2014, 14 (03) : 267 - 271
  • [30] Epigenetic Landscape of DNA Methylation in Pancreatic Ductal Adenocarcinoma
    Liu, Peiyi
    Jacques, Juliette
    Hwang, Chang-Il
    EPIGENOMES, 2024, 8 (04)
12345